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Abstract
A highly divergent synthesis of regioisomeric thiohydantoins and pseudothiohydantoins spiro-fused to a pharmacologically valu-
able pyrrole-2-one fragment involving the reaction of [e]-fused 1H-pyrrole-2,3-diones with thioureas was developed. The obtained
spiro pseudothiohydantoin derivatives were found to undergo a pseudothiohydantoin–thiohydantoin rearrangement. The reactions
were shown to proceed under catalyst-free conditions in good yields, and the products were isolated without applying preparative
chromatography methods.
Introduction
Hydantoin (imidazolidine-2,4-dione) derivatives are omni-
present among biologically active compounds [1]. Many of
them are commercially available drugs, for example, anticon-
vulsants phenytoin [2] and albutoin [3], the muscle relaxant
dantrolene [4], or the nonsteroidal antiandrogen agent enzalu-
tamide [5] (Figure 1).
Despite this fact, hydantoin derivatives belong to a special
group of scaffolds in medicinal chemistry. Indeed, they are
structurally related to rhodanine (2-thioxothiazolidin-4-one),
and sometimes are classified as pan-assay interference com-
pounds (PAINS), which are abhorrent in high-throughput
screenings [6]. To clarify whether such compounds are privi-
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Scheme 2: Syntheses of regioisomeric 5-spiro-substituted thiohydantoins and pseudothiohydantoins: previous [10] and this work.
Figure 1: Hydantoin-based commercially available drugs.
leged scaffolds or promiscuous binders, Mendgen and
co-workers performed a systematic comparative study on
rhodanines and related structures with respect to their medici-
nal chemistry properties [7]. As a result, it was shown that such
structures could be suitable scaffolds for medicinal chemistry
under proper conditions of biological evaluation, while their
medicinal chemistry properties dramatically depend on the
structure of the five-membered heterocyclic moiety and substit-
uents in the C-5 position [7].
Some pseudothiohydantoins (2-iminothiazolidin-4-ones) are
known to undergo a pseudothiohydantoin–thiohydantoin rear-
rangement (PTR, Scheme 1) [8-11], which is a special case of a
quite poorly investigated iminothiolactone–thiolactam rear-
rangement [12-16]. This reaction offers attractive opportunities
for the design of libraries of regioisomeric hydantoin-based
compounds for drug discovery.
Scheme 1: Pseudothiohydantoin–thiohydantoin rearrangement.
Spiro heterocycles are relatively new and insufficiently investi-
gated structures in medicinal chemistry [17,18]. The introduc-
tion of spiro-fused cyclic moieties in small molecules increases
the degree of their structural (shape) complexity, which may
lead to the reduced binding promiscuity and improved clinical
success [19]. Thus, recent development of 3D modelling
methods facilitated investigations on the importance of 3D
properties of small-molecular drug candidates [20-22] and
inspired chemists to develop diversity-oriented methods for
complex 3D molecules [23,24].
Considering that to the best of our knowledge, only a sole
report exists [10] that describes the synthesis of regioisomeric
5-spiro-substituted thiohydantoins and pseudothiohydantoins
and their PTR (Scheme 2), we were encouraged to develop a
divergent synthetic approach to access regioisomeric thiohydan-
toins and pseudothiohydantoins that are spiro-fused to a phar-
macologically valuable pyrrole-2-one fragment and to investi-
gate the scope and conditions of their PTR behavior
(Scheme 2).
Beilstein J. Org. Chem. 2019, 15, 2864–2871.
2866
Figure 2: Electrophilic centers of FPDs 1, starting materials of this
study.
Scheme 3: Cyclocondensation of FPDs 1 with 1,3-binucleophilic
reagents, resulting in pyrrole-2-one-bearing spiro[4.4] heterocycles.
Results and Discussion
1H-Pyrrole-2,3-diones fused at [e]-side (FPDs) 1 can be viewed
as a versatile polyelectrophilic synthetic platform (Figure 2),
enabling facile preparation of libraries of heterocyclic mole-
cules with an emphasis on skeletal diversity from a single set of
reagents [25-27].
One of the most intriguing chemical properties of FPDs 1 is
their ability to undergo a cyclocondensation with 1,3-binucle-
ophilic reagents to form spiro[4.4] heterocycles bearing a phar-
macophoric pyrrole-2-one moiety (Scheme 3) [28,29]. We em-
ployed this feature as a key step in the development of a
straightforward and concise synthetic approach towards regio-
isomeric thiohydantoins and pseudothiohydantoins spiro-fused
to a pyrrole-2-one fragment.
To test the preparation of the target spiro-fused pseudothiohy-
dantoins and thiohydantoins, we examined the reaction of FPD
1a with thiourea by heating equimolar amounts of the reagents
in toluene for 5 min (until the disappearance of the dark violet
color of FPD 1a). The reaction mixture was examined by
UPLC–MS. Two major products with m/z = 396 ([M + H]+,
ESI+) were observed in a ratio of ≈1:1, which corresponded to
adducts of thiourea with FPD 1a. The adducts were isolated,
and their structures were elucidated as the desired spiro-fused
thiohydantoin 2a and pseudothiohydantoin 3a (Scheme 4).
It should be pointed out that earlier, we have communicated
initial data on this transformation [30,31]. However, taking into
account more advanced structure elucidation methods em-
ployed in the present work (e.g., NMR, single crystal X-ray
Scheme 4: Reaction of FPD 1a with thiourea.
Scheme 5: PTR of 3a to 2a.
diffraction), we concluded that the structures of the products
were identified incorrectly, and they are revised herein (for a
detailed revision see Supporting Information File 1).
Next, to find out whether compounds 2a and 3a were prone to
undergo PTR, they were heated in open capillaries at 130 °C for
2 h, and the resulting mixtures were examined by UPLC–MS.
As a result, we found that compound 2a did not rearrange, and
compound 3a partially converted into its regioisomer 2a due to
irreversible PTR (Scheme 5).
Possibly, when carrying out the reaction of FPD 1a with thio-
urea by refluxing the reaction mixture in toluene, part of the
product 3a was converted into 2a because of PTR. We assumed
that at lower temperatures, the main product of the reaction
could be pseudothiohydantoin 3a. To prove this assumption, we
examined the reaction of FPD 1a with thiourea at room temper-
ature in various solvents (Table 1).
Obviously, the ratio of products 2a and 3a was dependent not
only on the temperature of the reaction, but also on the polarity
of the solvent. We found that optimal conditions for dominant
formation of pseudothiohydantoin 3a were applied by stirring
the reaction mixture at room temperature in ethyl or butyl
acetate (Table 1, entries 2 and 6).
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2 ethyl acetate 5:95
3 1,4-dioxane 50:50
4 acetic acid 30:70
5 acetonitrile 50:50
6 butyl acetate 5:95
7 toluene tracesc
aReaction mixtures were stirred until the disappearance of the dark
violet color of FPD 1a (about 2–4 h). bAccording to UPLC–MS data.
cThe reaction proceeded too slowly, and FPD 1a underwent hydroly-
sis faster than reaction with thiourea (the reaction vessel was contami-
nated with water during samplings for analyses).
For the development of a convenient procedure for thiohydan-
toin 2a without isolation of its regioisomer 3a being required,
we carried out the reaction of FPD 1a with thiourea in various
solvents under reflux (Table 2).




2 ethyl acetate 22:78c
3 1,4-dioxane 90:10c
4 1,4-dioxane 99:1d
5 acetic acid 30:70c
6 acetonitrile 25:75c
7 butyl acetate 95:5c
8 toluene 50:50c
aReaction mixtures were refluxed until the disappearance of the dark
violet color of FPD 1a (about 5–15 min). bAccording to UPLC–MS
data. cThe reagents were mixed prior the heating. dThiourea was
added to a boiling solution of FPD 1a.
As a result of this optimization, we established that thiohydan-
toin 2a was formed as major product upon refluxing the reac-
tion mixture in butyl acetate or 1,4-dioxane (Table 2, entries 3,
4, and 7). Interestingly, at different reagent ratios, the yield of
compound 2a was affected as well (Table 2, entries 3 and 4).
When the reagents were mixed prior to heating (Table 2, entry
3), the yield of compound 2a was lower than when the reagents
were mixed in the boiling solvent (Table 2, entry 4). Probably,
compound 2a was formed not only as a result of the corre-
sponding PTR, but as a result of a concurrent attack of the
amino group of thiourea on the C-3a atom of FPD 1a
(Scheme 6).
Scheme 6: Pathways for the formation of compound 2a.
Using the optimization data, we obtained a series of spiro-fused
thiohydantoins 2a–m and pseudothiohydantoins 3a–m by
utilizing various FPDs 1a–n (Table 3). The aryl group-bearing
FPDs 1a–m reacted facilely to yield the desired compounds 2
and 3, but ethoxycarbonyl group-bearing FPD 1n reacted unse-
lectively, giving a complex mixture of hardly identifiable prod-
ucts due to the occurrence of multiple side reactions involving
the ethoxycarbonyl group.
Next, we examined the influence of substituents in the thiourea
motif on its reaction with FPDs 1. It was found that monosub-
stituted thioureas (N-methylthiourea, N-phenylthiourea, N-(4-
chlorophenyl)thiourea, N-(3,5-dimethylphenyl)thiourea, N-(4-
nitrophenyl)thiourea, and N-1-naphtylthiourea) reacted with
FPD 1a unselectively, forming a mixture of four inseparable
adducts (the reaction mixtures were analyzed by UPLC–MS)
(Scheme 7). Unfortunately, we did not succeed to find any
conditions for a selective formation of either of them.
Unexpectedly, the implementation of N-acetylthiourea in the
reaction with FPDs 1, both under conditions A and B (see Ta-
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Table 3: Series of spiro-fused thiohydantoins 2a–m and pseudothiohydantoins 3a–m from various FPDs 1a–n.
Entry R R' Yield of 2 (%)a,b Yield of 3 (%)a,c
a 2-OH-C6H4 Ph 97
(CCDC 1952743)
79
b 5-Cl-2-OH-C6H3 Ph 78 87
c 2-OH-C6H4 4-OMe-C6H4 79 91
d 2-OH-C6H4 4-OEt-C6H4 90 79
e 2-OH-C6H4 4-Cl-C6H4 78 61
(CCDC 1952745)
f 2-OH-C6H4 4-Br-C6H4 87 61
g 2-OH-C6H4 4-Me-C6H4 89 89
h 5-NO2-2-OH-C6H3 Ph 95 58
i 2-OH-C6H4 4-NO2-C6H4 61 53
j 5-Br-2-OH-C6H3 Ph 65 59
k 2-OH-C6H4 4-F-C6H4 81 82
l CH2CH2OH 4-Cl-C6H4 90
(CCDC 1952798)
97
m CH2CH2OH 4-Me-C6H4 98 75
n 2-OH-C6H4 OEt – –
aIsolated yields. bConditions A: a mixture of FPD 1a–n (1 mmol) and thiourea (1 mmol) was refluxed in 1,4-dioxane (5 mL) for 4 h. cConditions B: a
mixture of FPD 1a–n (1 mmol) and thiourea (1 mmol) was stirred in ethyl acetate (5 mL) for 12 h at room temperature.
Scheme 7: Reaction of FPD 1a with monosubstituted thioureas.
ble 3), afforded only one type of adducts, pseudothiohydan-
toins 4 (Table 4). Boiling compounds 4 in various solvents and
heating them in open capillaries at 130 °C for 12 h did not
provoke PTR, and compounds 4 remained unconverted. This
phenomenon could be explained by the influence of the elec-
tron-withdrawing effect of the acetyl group, which reduced the
nucleophilic properties of the acetyl-substituted nitrogen atom
in N-acetylthiourea and decreased its reactivity, preventing the
formation of regioisomeric compounds.
1,3-Dibutylthiourea reacted smoothly at room temperature in
ethyl acetate with FPDs 1 to form mixtures of products 5 and 6
(Scheme 8). Moreover, it was observed that the percentage of
compounds 5 in reaction mixtures increased over time upon
storage of the solutions. As such, 6 readily underwent PTR,
affording the corresponding compounds 5, but unfortunately,
we did not succeed to isolate pseudothiohydantoins 6.
The reaction of FPDs 1 with 1,3-dibutylthiourea in 1,4-dioxane
resulted in exclusive formation of thiohydantoins 5 upon
heating at reflux for 2–4 h (Table 5).
The facility of thiohydantoins 5 formation could be explained
by the electron-donating effect of the butyl substituents, which
Beilstein J. Org. Chem. 2019, 15, 2864–2871.
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Table 4: bReaction of FPDs 1 with N-acetylthiourea.
Product Ar R Yield of 4 (%)a
4ab Ph H 80
4b 4-Cl-C6H4 H 75
4c Ph Cl 79
aIsolated yields. bCCDC 1952746.
Scheme 8: Reaction of FPDs 1 with 1,3-dibutylthiourea at room tem-
perature.
increased the nucleophilicity of the butyl-substituted nitrogen
atoms and promoted its attack on the electrophilic center C-3a
of FPDs 1.
The reaction of FPDs 1 with 1,3-diphenylthiourea proceeded in
a similar manner. Thiohydantoins 7 were predominantly formed
when the reaction was conducted at reflux in 1,4-dioxane, and
Table 5: Reaction of FPDs 1 with 1,3-dibutylthiourea at reflux.
Product Ar R Yield of
5 (%)a
5a Ph 2-OH-C6H4 75
5bb Ph 5-Cl-2-OH-C6H3 76
5c 4-Cl-C6H4 CH2CH2OH 76
aIsolated yields. bCCDC 1952744.
pseudothiohydantoins 8 were formed as main products at room
temperature (Table 6).
Notably, the formation of thiohydantoins 7 required longer time
in comparison with unsubstituted thiourea and 1,3-dibutylthio-
urea. Possible reasons for this are the influence of the steric
hindrance induced by the phenyl substituents and weakening of
the nucleophilic properties of the phenyl-substituted nitrogen
atom, which prevented a nucleophilic attack of 1,3-diphenyl-
thiourea on the electrophilic center C-3a of FPDs 1.
The observed PTRs could have proceed through two alternative
pathways (Scheme 9), with the first stage being dissociation of
the Cspiro–S bond [32] in pseudothiohydantoins PThH,
affording intermediate A. Then, A could have further under-
gone either an intramolecular cyclization by NH attack, forming
thiohydantoin ThH (path A), or further dissociation to FPD 1
and thiourea. The latter would subsequently attack FPD 1 with
both nucleophilic NH centers, forming thiohydantoin ThH
(path B).
Conclusion
In conclusion, we have developed a divergent approach to phar-
maceutically interesting regiomeric thiohydantoins and
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Scheme 9: Plausible PTR pathways.
Table 6: Reaction of FPDs 1 with 1,3-diphenylthiourea.




a Ph 2-OH-C6H4 71 78
b 4-Cl-C6H4 CH2CH2OH 63 82
c 4-Me-C6H4 CH2CH2OH 72 76
aIsolated yields. bConditions A: a mixture FPD 1 (1 mmol) and 1,3-
diphenyl-thiourea (1 mmol) was refluxed in 1,4-dioxane (5 mL) for
8–12 h. cConditions B: a mixture FPD 1 (1 mmol) and 1,3-diphenyl-
thiourea (1 mmol) was stirred in ethyl acetate (5 mL) for 12 h at room
temperature.
pseudothiohydantoins spiro-fused to a pyrrole-2-one fragment
via the reaction of [e]-fused 1H-pyrrole-2,3-diones with
thioureas. The obtained pseudothiohydantoins were found to be
prone to undergo a pseudothiohydantoin–thiohydantoin rear-
rangement. Therein, the substituents of the thiourea moiety
were found to be crucial for tuning the conditions of this rear-
rangement. Notably, the reactions proceeded under catalyst-free
conditions with good yields.
Supporting Information
Supporting Information File 1
Experimental details, copies of 1H and 13C NMR spectra,
X-ray crystallographic details, references to antimicrobial
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